BlueSavant AI
BlueSavant AI is a pre-revenue US healthcare diagnostics company developing BSAI DFx, a proprietary RNA-sequencing and machine learning blood test that screens children as young as 18 months for autism, serving pediatricians and parents pending CAP CLIA accreditation.
- Company typePrivate
- Founded2024
- HeadquartersWilmington, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What BlueSavant AI does
BlueSavant AI is a Wilmington, Delaware-based, privately held healthcare diagnostics company founded in 2024 that is developing BSAI DFx (BlueSavant AI Diagnostic Framework), a blood-based screening test for autism spectrum disorder. The product uses a 1ml blood sample, derives gene expression profiles through RNA sequencing across approximately 20,000 genes, and applies a proprietary machine learning model to classify autism status and predict phenotypic characteristics potentially impacted by autism over time. The company reports 88% sensitivity in detecting autism-positive cases in children as young as 18 months, positioning the test as substantially more accurate than Whole Exome Sequencing (30%), Chromosomal Micro-Array (3%), and FMR1/FXS testing (3%).
The business model is a one-time diagnostic test fee per patient, ordered through a healthcare provider prescription and a companion mobile application, with samples processed in the company's laboratory. Target customers are pediatricians and developmental specialists on the B2B side, and parents of young children on the demand-pull side; the company emphasizes the pain points of average 5-year-old diagnosis ages, 4+ month therapy wait times, 15 assessment sessions, and $10,000 in pre-diagnosis healthcare costs as the wedge for adoption. The company is currently working toward CAP CLIA accreditation required for US clinical laboratory operation and is not yet generating revenue. A priority list subscription is being collected for early access, with the first 100 subscribers offered the test at half price post-approval.
Strategically, BlueSavant AI is in a pre-commercial, ecosystem-building phase: it is participating in the Caelestinus accelerator, exhibited at Web Summit Qatar 2025 as an IMPACT startup aligned with UN SDG 3, and has generated press through Chief Scientist Dr. Hugh Cam's media appearances. Funding is undisclosed, with a January 2025 funding round recorded in the dataset. The technical premise — RNA-based dynamic gene expression versus static DNA-based methods — is the company's principal differentiator and the foundation of its claimed data flywheel: the company states that model performance improves with each additional test performed.
BlueSavant AI firmographics
Firmographics- Name
- BlueSavant AI
- Legal name
- BlueSavant AI
- Website
- https://bluesavant.net
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BlueSavant AI is a pre-revenue US healthcare diagnostics company developing BSAI DFx, a proprietary RNA-sequencing and machine learning blood test that screens children as young as 18 months for autism, serving pediatricians and parents pending CAP CLIA accreditation.
- Ownership category
- akta.pro rank
BlueSavant AI industry classification
Industry- Product category
- Autism Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Autism Diagnostic & Educational Assessment Services (EDAKAKAA)
- akta.pro secondary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
Keywords
Where BlueSavant AI is headquartered
LocationHeadquarters
- HQ city
- Wilmington
- HQ country
- United States
- HQ region
- North America
Markets served
BlueSavant AI business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- BSAI DFx Diagnostic Test: One-time diagnostic test service involving blood sample collection, RNA gene expression analysis, and autism classification report. The test is prescribed by healthcare providers and ordered through a mobile application. Currently awaiting regulatory approval (CAP CLIA accreditation) for US market launch.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
BlueSavant AI product offering
Product offeringCore offering
BlueSavant AI develops and offers BSAI DFx, a blood-based autism diagnostic test that uses a 1ml blood sample to derive gene expressions through RNA sequencing and analyzes them via a proprietary machine learning model to identify autism in children as young as 18 months. The test achieves 88% sensitivity in detecting autism-positive cases and predicts phenotypic characteristics potentially impacted by autism. The company distributes the test through healthcare provider prescriptions with ordering via a companion mobile application, and is currently pursuing CAP CLIA accreditation for US market launch.
Product overview
BlueSavant AI offers a single unified diagnostic product called BSAI DFx (BlueSavant AI Diagnostic Framework), a blood-based autism screening test that leverages RNA sequencing and proprietary machine learning. The company also provides a companion mobile application for test ordering. The BSAI DFx is designed for children as young as 18 months and can detect approximately 88% of autism-positive cases.
Differentiator
Problem solved
Functional benefit
Brands
- BSAI DFx: BlueSavant AI Diagnostic Framework - a blood test utilizing gene expressions and machine learning to proactively identify autism in children as young as 18 months, achieving 88% sensitivity in detecting autism-positive cases.
Products and services
- BSAI DFx (BlueSavant AI Diagnostic Framework) A blood-based autism diagnostic test that uses a 1ml blood sample to derive gene expressions via RNA sequencing, analyzed through a proprietary machine learning model to identify autism in children as young as 18 months before symptoms appear. Detects approximately 88% of autism-positive cases and predicts phenotypic characteristics potentially impacted by autism over time. Prescribed by pediatricians and developmental specialists and ordered through the BSAI mobile application.
Quantifiable outcome
- 88% sensitivity rate for autism detection (vs. 30% for WES, 3% for CMA)
- +3 more outcomes
Companies that use BlueSavant AI
Customer profileSegments2 records
Ideal customer profiles2 records
BlueSavant AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature3 records
BlueSavant AI partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Web Summit QatarminorBlueSavant AI is exhibiting at Web Summit Qatar 2025 (Feb 23-26), participating as an IMPACT startup aligned with UN's SDG 3: Good Health and Well-being.
- Caelestinus AcceleratorcoreBlueSavant AI is participating in the Caelestinus accelerator program, which supports early-stage healthcare and biotech companies in advancing their technologies and market positioning.
- Boston Entrepreneurs' Network at Lasell UniversityminorBlueSavant AI participated in Boston Entrepreneurs' Network event at Lasell University, where company representatives discussed AI applications in healthcare and disease prediction.
- Alhurra TV ChannelminorChief Scientist Dr Hugh Cam provided an exclusive interview for Alhurra TV Channel in Dubai, explaining autism diagnosis complexities and BSAI DFx capabilities.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
BlueSavant AI competitors and assessment
Company assessmentBroad incumbents
- Illumina: Illumina is the dominant sequencing platform provider whose RNA-seq technology underpins BSAI DFx. It is a relevant comparator for sequencing cost trajectories, instrument dependencies, and the broader ecosystem BlueSavant relies on.
- GeneDx (Sema4): GeneDx is a clinical genetic testing laboratory offering whole-exome and genome sequencing, including for pediatric neurodevelopmental disorders. It is a comparable commercial lab scaling rare-disease and pediatric genetic testing.
- Myriad Genetics: Myriad is a large, established molecular diagnostics company with genetic tests across multiple conditions including neurological and psychiatric disorders. It is a relevant incumbent comparator for commercialization, reimbursement, and sales-force buildout.
- Quest Diagnostics: Quest is one of the largest US clinical laboratory networks with broad pediatric and genetic test menus. It represents the scale incumbent BlueSavant would need to displace or partner with for nationwide pediatric test distribution.
- Laboratory Corporation of America (Labcorp): Labcorp operates an extensive US clinical lab business with established pediatric, genetic, and specialty testing lines. It is a natural comparator for the lab-services scale, logistics, and payer relationships BlueSavant will eventually need.
Emerging players
- Tempus Labs: Tempus applies AI/ML to multi-omic data (including RNA sequencing) for clinical diagnostics and drug discovery. Its technology stack and machine-learning-on-biology approach are directly analogous to BSAI DFx's architecture.
- Stemina Biomarker Discovery: Stemina develops blood-based biomarker diagnostics for autism and related neurological conditions using metabolomics and cell-based assays. It overlaps with BlueSavant in pursuing a blood-based, non-behavioral autism diagnostic.
Direct peers
- Quadrant Biosciences: Quadrant Biosciences developed Clarifi, an RNA-based saliva epigenetic test for autism. It is the closest direct competitor to BlueSavant's RNA-based, ML-driven autism diagnostic, addressing the same pediatric population with a similar biological-signal approach.
- Lineagen: Lineagen offers genetic testing (including microarray and sequencing-based assays) specifically focused on autism and other neurodevelopmental disorders. It competes for the same pediatric diagnostic workup that BSAI DFx targets.
- SynapDx (Roche): SynapDx was a blood-based RNA gene-expression autism diagnostic acquired by Roche in 2015. It pioneered the same blood-plus-RNA autism test category BlueSavant is now pursuing and remains the canonical comparable for this approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
BlueSavant AI social profiles
Digital presenceBlueSavant AI compliance and trust
Trust signalCompliance1 record
BlueSavant AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
BlueSavant AI leadership team
Management profileNumber of profiles
Profiles1 record
BlueSavant AI funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BlueSavant AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BlueSavant AI
What does BlueSavant AI do?
BlueSavant AI develops and offers BSAI DFx, a blood-based autism diagnostic test that uses a 1ml blood sample to derive gene expressions through RNA sequencing and analyzes them via a proprietary machine learning model to identify autism in children as young as 18 months. The test achieves 88% sensitivity in detecting autism-positive cases and predicts phenotypic characteristics potentially impacted by autism. The company distributes the test through healthcare provider prescriptions with ordering via a companion mobile application, and is currently pursuing CAP CLIA accreditation for US market launch.
Is BlueSavant AI a public or private company?
BlueSavant AI is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was BlueSavant AI founded?
BlueSavant AI was founded in 2024. It employs 1 to 10 people.
Where is BlueSavant AI based?
BlueSavant AI is headquartered in Wilmington, United States, in the North America region.
How does BlueSavant AI make money?
One revenue line is on record: BSAI DFx Diagnostic Test.
Who are BlueSavant AI's main competitors?
Broad incumbents on record are Illumina, GeneDx (Sema4), Myriad Genetics, Quest Diagnostics and Laboratory Corporation of America (Labcorp). Emerging players are Tempus Labs and Stemina Biomarker Discovery. Direct peers are Quadrant Biosciences, Lineagen and SynapDx (Roche).
Does BlueSavant AI have an API?
No public API is recorded for BlueSavant AI.
What industry is BlueSavant AI in?
BlueSavant AI's product category is Autism Diagnostics. Its primary akta.pro industry code is EDAKAKAA, Autism Diagnostic & Educational Assessment Services, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 621511 and its SIC code is 2835.